Demographics Clinical Presentation And Outcome Of Gist Patients Treated With Imatinib At Tikur Anbessa Specialized Hospital Addis Ababa Ethiopia An Eleven -year Retrospective Study

Background: Gastrointestinal stromal tumor (GIST) is a mesenchyme tumor located primarilyrnin the stomach and small intestine, but can occur in any portion of the alimentary tract includingrnoccasionally in the omentum, mesentery, and peritoneum. Up to 80 % of GISTs result from gainof-functionrnmutationsrninrnthernKITrngene,rnandrnapproximatelyrn85–95rn%rnofrnGISTsrnstainrnpositivernforrnrnthernKITrnproteinrn(CD117).rnTherernirnslightrnincreasesrnprevalencerninrnmales.rnThernmedianrnagernisrnaroundrnrn60–65rnyearsrninrnwesternrnpopulation.rnThernusernofrnimatinibrntornselectivelyrninhibitrnKITrnandrnPDGFRArnrnreceptorrntyrosinernkinasesrnisrnhighlyrneffectiverninrntherntreatmentrnofrnmetastaticrnGISTrnandrnasrnadjuvantrnrntreatment.rnrnObjective :The main objective of this to study to characterize ,Demographics, ClinicalrnPresentation and Outcome of GIST Patients Treated with Imatinib at Tikur Anbessa SpecializedrnHospital, Addis Ababa, Ethiopia. rnMethod: A retrospective cross sectional design, patients with GIST enrolled in the GlivecrnInternational Patient Assistance Program (GIPAP) from January 1 2004 to August 30, 2021. Allrnadult patients diagnosed with advanced GIST and adjunctive imatinib treatments were includedrnand treatment response assessed using response evaluation criteria in solid tumors (RECIST). rnResults: There are more than hundred GIST patients on imatinib at hematology clinic at TASH.rnFifty eight patients with pathologically confirmed GIST, with abdominal CT scan takingrnimatinib were enrolled. The median age is 52 (ranges 20-83). 27.6% of were less than 45 age.rnThirty two (55%) of GIST patients were male and twenty six (45%) were females with slightrnmale predominance. Thirty seven (64%) had tumor originated from stomach and, twenty twornpatients had metastatic stage 4 disease. Metastasis to liver was the commonest site occurred inrnnine (15.5%). Surgical resection was the most frequent treatment; done for fifty (86.2%) patients.rnmedian duration of treatment with imatinib were 2.9 years. Out of sixteen patients withrnmetastatic diseases, six (37.5) achieved PR, three (18.75) had SD four (25%) had PD. From arntotal of forty two patients taking adjunctive imatinib treatment thirty three (78.5%) achieved CR,rnand eight (19) patients was in PR. rnConclusion: This study showed Imatinib had a high efficacy both in patients with unresectablernGIST/metastatic GIST and in those given as adjuvant treatments at the TASH.However it wasrnmore effective as adjuvant treatment.

Get Full Work

Report copyright infringement or plagiarism